



FEE TRANSMITTAL

RECEIVED

JAN 2 8 2003

TECH CENTER 1600/2900

Application Number 10/022,862
Filing Date December 13, 2001
Confirmation No. 4104
Inventor(s) M. Chukowicz et al.
Group Art Unit 1651
Examiner Name M. Meller
Attorney Docket Number PHA 4140.7(3475/1)

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- ☐ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- ☐ Applicant claims small entity status.
2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

FEE CALCULATION

1. ☐ BASIC FILING FEE Subtotal (1) \$ _____
(Type:)
2. ☐ EXTRA CLAIM FEES Subtotal (2) \$ _____
Total Claims _____
Independent Claims _____
Multiple Dependent Claims _____
3. ☒ ADDITIONAL FEES Subtotal (3) \$ 110.00
 - ☐ Surcharge - late filing fee or oath
 - ☐ Surcharge - late provisional filing fee or cover sheet
 - ☒ Extension for reply within First month
 - ☐ Notice of Appeal
 - ☐ Filing a Brief in Support of an appeal
 - ☐ Request for ex parte Reexamination
 - ☐ Petitions to the Commissioner
 - ☐ Submission of Information Disclosure Statement
 - ☐ Recording each patent assignment per property
 - ☐ Request for Continued Examination
 - ☐ Other: _____


TOTAL AMOUNT OF PAYMENT \$ 110.00

Timothy B. McBride, Reg. No. 47,781

January 24, 2003
Date

TBM/sxm

Express Mail Label No. EV 224267105 US



1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit 1651

RECEIVED
JAN 28 2003
CH CENTER 1000/2000

JAN 28 2007

JECH CENTER 1800/2800

January 24, 2003

Examiner M. Meller

RESPONSE TO OFFICE ACTION

TO THE ASSISTANT COMMISSIONER FOR PATENTS,

SIR:

In response to the Office action dated September 24, 2002, please enter the following amendments:

AMENDMENT A

IN THE CLAIMS:

Please amend the claims as follows:

1. (amended) A method of treating an organism for a condition which is mediated by COX-2 expression, the method comprising the step of orally, parenterally, or rectally administering to the organism a composition comprising a therapeutically or prophylactically effective COX-2 inhibiting amount of an organic extract of a plant, wherein the extract selectively inhibits the activity of COX-2 relative to COX-1 as determined in vitro by an IC_{50} ratio of COX-1/COX-2, and wherein the plant is selected from the order consisting of Agavales, Apocynales, Arales, Asterales, Basidiomycetae, Brassicales, Caryophyllales, Cycadales, Ebenales, Euphorbiales, Fagales, Hydrocharitales, Lamiales, Liliales, Loasales, Malvales, Myrtales, Palmales, Pandanales,